GeoVax Labs, a clinical-stage biotechnology company, has made significant strides in developing innovative vaccines and therapies for COVID-19 and cancer in 2024, positioning itself for potentially transformative medical breakthroughs.
The company's lead COVID-19 vaccine candidate, GEO-CM04S1, is progressing through multiple Phase 2 clinical trials, including a major 10,000-participant study funded by the Biomedical Advanced Research and Development Authority (BARDA). The vaccine aims to address critical gaps in vaccination for immunocompromised patients and provide enhanced protection against emerging COVID-19 variants.
In oncology, GeoVax is advancing Gedeptin, a gene-directed therapy for head and neck cancers, with plans to initiate a Phase 2 clinical trial combining the treatment with an immune checkpoint inhibitor. The company estimates a potential market opportunity of $15 billion for this innovative approach to treating solid tumors.
The company is also developing GEO-MVA, a vaccine candidate targeting Mpox and Smallpox, with clinical evaluations expected to begin in late 2025. This development comes in response to recent public health emergencies and aims to reduce dependence on foreign vaccine manufacturers.
Financially, GeoVax reported a net loss of $25.0 million for 2024, slightly improved from $26.0 million in 2023. The company secured $4.0 million in government contract revenues and continues to strengthen its intellectual property portfolio with over 130 granted or pending patents across 23 different families.
These developments underscore GeoVax's commitment to addressing critical medical needs and developing innovative therapies with significant market potential across infectious diseases and oncology.
